{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:45:09Z","timestamp":1773866709170,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T00:00:00Z","timestamp":1335484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00417-012-2016-6","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T01:29:52Z","timestamp":1335403792000},"page":"787-793","source":"Crossref","is-referenced-by-count":22,"title":["Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review"],"prefix":"10.1007","volume":"250","author":[{"given":"Taygan","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cordero-Coma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,27]]},"reference":[{"issue":"2","key":"2016_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000309923","volume":"197","author":"R David","year":"1988","unstructured":"David R, Zangwill L, Badarna M, Yassur Y (1988) Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 197(2):69\u201374","journal-title":"Ophthalmologica"},{"key":"2016_CR2","first-page":"133","volume":"98","author":"R Klein","year":"2000","unstructured":"Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133\u2013141, discussion 141\u2013133","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"10","key":"2016_CR3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","volume":"114","author":"P Mitchell","year":"1996","unstructured":"Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114(10):1243\u20131247","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"2016_CR4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri M, Chen E, Looman M, Gallagher M (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye 25(8):981\u2013988","journal-title":"Eye"},{"issue":"2","key":"2016_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00417-010-1440-8","volume":"249","author":"S Moradian","year":"2011","unstructured":"Moradian S, Faghihi H, Sadeghi B, Piri N, Ahmadieh H, Soheilian M, Dehghan MH, Azarmina M, Esfahani MR (2011) Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3\u00a0months (Report 1). Graefes Arch Clin Exp Ophthalmol 249(2):193\u2013200","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"2016_CR6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.survophthal.2010.11.006","volume":"56","author":"JP Ehlers","year":"2011","unstructured":"Ehlers JP, Fekrat S (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 56(4):281\u2013299","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"2016_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","volume":"98","author":"The Branch Vein Occlusion Study Group","year":"1984","unstructured":"The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271\u2013282","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2016_CR8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2007.01.010","volume":"114","author":"RL McIntosh","year":"2007","unstructured":"McIntosh RL, Mohamed Q, Saw SM, Wong TY (2007) Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(5):835\u2013854","journal-title":"Ophthalmology"},{"issue":"3","key":"2016_CR9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","volume":"50","author":"M Funk","year":"2009","unstructured":"Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50(3):1025\u20131032","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2016_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.eye.6702498","volume":"22","author":"H Noma","year":"2008","unstructured":"Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22(1):42\u201348","journal-title":"Eye"},{"issue":"3","key":"2016_CR11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.2007.123513","volume":"92","author":"TC Kreutzer","year":"2008","unstructured":"Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92(3):351\u2013355","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2016_CR12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","volume":"92","author":"K Kriechbaum","year":"2008","unstructured":"Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92(4):518\u2013522","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2016_CR13","first-page":"424","volume":"33","author":"CH Chen","year":"2010","unstructured":"Chen CH, Chen YH, Wu PC, Chen YJ, Lee JJ, Liu YC, Kuo HK (2010) Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J 33(4):424\u2013435","journal-title":"Chang Gung Med J"},{"issue":"3","key":"2016_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3129\/i10-027","volume":"45","author":"JA Micieli","year":"2010","unstructured":"Micieli JA, Micieli A, Smith AF (2010) Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol 45(3):231\u2013238","journal-title":"Can J Ophthalmol"},{"issue":"6964","key":"2016_CR15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","volume":"309","author":"K Dickersin","year":"1994","unstructured":"Dickersin K, Scherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. BMJ 309(6964):1286\u20131291","journal-title":"BMJ"},{"issue":"1","key":"2016_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"2016_CR17","unstructured":"Higgins J, Green S (2006) Cochrane Handbook for Systematic Reviews of Interventions 4.2.6: Section 6. The Cochrane Library 4"},{"issue":"10","key":"2016_CR18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3109\/02713683.2010.496540","volume":"35","author":"O \u00c7eki\u00e7","year":"2010","unstructured":"\u00c7eki\u00e7 O, Cakir M, Yazici AT, Alagoz N, Bozkurt E, Faruk Yilmaz O (2010) A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res 35(10):925\u2013929","journal-title":"Curr Eye Res"},{"issue":"4","key":"2016_CR19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/IAE.0b013e318195ca65","volume":"29","author":"V Russo","year":"2009","unstructured":"Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 29(4):511\u2013515","journal-title":"Retina"},{"issue":"12","key":"2016_CR20","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1038\/eye.2008.429","volume":"23","author":"WC Wu","year":"2009","unstructured":"Wu WC, Cheng KC, Wu HJ (2009) Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 23(12):2215\u20132222","journal-title":"Eye"},{"issue":"12","key":"2016_CR21","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/bjo.2008.137604","volume":"92","author":"AE Fung","year":"2008","unstructured":"Fung AE, Bhisitkul RB (2008) Safety monitoring with ocular anti-vascular endothelial growth factor therapies. Br J Ophthalmol 92(12):1573\u20131574","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"2016_CR22","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","volume":"114","author":"Diabetic Retinopathy Clinical Research Network","year":"2007","unstructured":"Network Diabetic Retinopathy Clinical Research, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10):1860\u20131867","journal-title":"Ophthalmology"},{"issue":"20","key":"2016_CR23","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897\u20131908","journal-title":"N Engl J Med"},{"issue":"6","key":"2016_CR24","first-page":"1226 e1221","volume":"116","author":"DB Roth","year":"2009","unstructured":"Roth DB, King A, Weiss M, Klein D (2009) Systemic adverse events after bevacizumab. Ophthalmology 116(6):1226 e1221","journal-title":"Ophthalmology"},{"issue":"6","key":"2016_CR25","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","volume":"116","author":"M Soheilian","year":"2009","unstructured":"Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116(6):1142\u20131150","journal-title":"Ophthalmology"},{"issue":"5","key":"2016_CR26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ophtha.2009.02.002","volume":"116","author":"T Yilmaz","year":"2009","unstructured":"Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, Lavaque AJ, Larson RJ (2009). Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 116(5):902\u2013911, quiz 912\u2013903","journal-title":"Ophthalmology"},{"issue":"8","key":"2016_CR27","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594\u20131602","journal-title":"Ophthalmology"},{"issue":"6","key":"2016_CR28","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1167\/iovs.10-5842","volume":"52","author":"S Sacu","year":"2011","unstructured":"Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, Schmetterer L, Schmidt-Erfurth U (2011) Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52(6):3046\u20133050","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"2016_CR29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/archopht.124.10.1478","volume":"124","author":"MC Gillies","year":"2006","unstructured":"Gillies MC (2006) What we don't know about Avastin might hurt us. Arch Ophthalmol 124(10):1478\u20131479","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2016_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/88842","volume":"28","author":"B Oosthuyse","year":"2001","unstructured":"Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28(2):131\u2013138","journal-title":"Nat Genet"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-012-2016-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-012-2016-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-012-2016-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:48:17Z","timestamp":1559058497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-012-2016-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s00417-012-2016-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,27]]}}}